UTHR
United Therapeutics Corporation
532.80$
-2.2%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +2.0% | -9.4% | +3.5% | +5.9% | +3.4% | +5.2% | +2.1% | -7.0% | +7.2% | -14.8% | +7.5% | |
| – | +2.7% | -8.5% | +11.4% | +10.5% | -3.2% | +1.7% | -2.9% | -8.7% | +6.0% | -22.4% | +21.3% | |
| – | +9.0% | +3.6% | +8.3% | +14.6% | +9.2% | +11.9% | -16.1% | -28.7% | +37.0% | -31.0% | +67.9% | |
| – | +4.1% | -9.6% | +9.7% | +11.9% | -1.8% | +1.7% | -8.2% | -9.2% | -43.7% | +38.3% | +23.6% | |
| – | +7.8% | +10.2% | -5.4% | +17.6% | -18.3% | +15.3% | +17.8% | -21.5% | +17.6% | -10.9% | -0.5% | |
| – | +7.2% | +7.5% | +13.6% | +7.5% | +7.6% | +4.7% | +2.3% | +4.3% | +3.7% | -2.6% | +8.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +81.3% | +43.4% | -0.2% | -2.7% | -29.0% | +40.3% | -0.2% | +4.7% | -0.2% | -0.9% | -1.2% | |
| – | -9.9% | -2.1% | -11.3% | -0.4% | -10.0% | +1.8% | -21.6% | +3.6% | +3.0% | +3.7% | +0.8% | |
| – | +8.1% | +7.0% | -3.3% | +4.9% | -15.5% | -2.2% | -26.9% | +3.6% | +2.6% | +6.9% | +1.5% | |
| – | +33.3% | +0.0% | +0.0% | +0.0% | -25.0% | -33.3% | – | – | – | – | – | |
| – | -98.3% | +5,348.2% | +6.6% | +11.9% | -98.4% | +6,016.7% | +17.7% | +8.3% | -98.5% | +6,918.3% | -0.1% | |
| – | -40.0% | -33.3% | -50.0% | – | – | – | – | – | – | – | – | |
| – | +4.8% | -10.8% | +6.7% | +7.1% | +5.6% | +5.6% | +5.4% | -8.1% | +7.7% | -16.8% | +8.5% | |
| – | +3.7% | +5.1% | +4.4% | +4.7% | +4.4% | +4.5% | +4.1% | +4.3% | +4.4% | +3.2% | +3.8% | |
| – | +0.2% | -0.2% | -4.4% | +1.9% | +0.6% | -0.2% | -0.6% | -2.1% | +1.3% | -1.5% | -3.0% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.